Home |  Products |  Bios |  News |  Contact Us |  FAQ
  Independent Research on Corporate Bonds Since 1994 Preferences|Login

   March 6, 2015 @ 3:56 AM EST
Investment Grade
AbbVie  (with Analyst's Data SheetAfter wasting considerable time and money trying to acquire Shire, AbbVie is on the acquisition hunt again. Its $21 billion purchase of Pharmacyclics seems pricey by...
Charles Schwab  (with Analyst's Data SheetCharles Schwab is not a frequent debt issuer, but the company tapped the markets earlier this week, pricing $1.0 billion in three ($625 million) and...
High Yield
Pilgrim's Pride  (with Analyst's Data SheetPilgrim's Pride popped into the hungry high yield market this week with a quickly shopped $500 million issue of new 10-year senior notes priced with a...
4:24pm Pilgrim's Pride As we projected back in January Pilgrim's Pride decided to tap the high yield market to...
1:26pm Newfield Exploration and Production Newfield Exploration (NFX) is looking to issue $500 million of...
1:05pm Canadian Natural Resources Limited Canadian Natural Resources reported very good fourth quarter...
11:36am AbbVie Late last night, perhaps aware of press leaks, AbbVie announced it was buying Pharmacyclics for $21...
Investment Grade
Orange SA  (with Analyst's Data SheetAfter suggesting that a combination with Telecom Italia could be a great opportunity for European consolidation, Orange CEO Stephane Richard subsequently...
Best Buy  (with Analyst's Data SheetUnder pressure from shareholders to distribute some of its cash, Best Buy announced a new "capital return to shareholders" plan as well as improved fiscal fourth...
High Yield
J.C. Penney  (with Analyst's Data SheetJ.C. Penney's (JCP) fiscal 2014 fourth quarter adjusted EBITDA was a little short of consensus expectations as stronger same store sales were offset by less...
Chesapeake 3/4 
Ensco 2/26 
Martin Marietta Materials 2/10 
Wendy's 2/5 
ConocoPhillips 2/5 
An Independent Viewpoint
Rigorous Analysis
Coverage of Key Securities
Every report is one page, and concludes with an actionable investment recommendation.
Mar 4, 2015 | Financial Post
VB on Valeant Pharmaceuticals International Inc faces high execution risk Q - "With Salix and Dendreon in the hopper, Valeant could be facing its highest and most difficult execution risks ever."
Mar 2, 2015 | Bloomberg
CL on Actavis Cuts Cost on $21 Billion Bond Deal With Buyers Swarming Q - "Actavis is a relatively high-yielding name in a relatively stable industry that probably will be highly liquid."
Mar 2, 2015 | DBR High Yield Weekly
KN on New Pet Owner Q - PetSmart report featured
Mar 2, 2015 | The Street
VB on American Air Shares Decline Despite Credit Rating Upgrade Q - "Cash and liquidity is restored to a more comfortable range with little noticeable impact to our projected yearend leverage of 2x - a nice improvement versus 3.8x at the end of 2014."
Feb 26, 2015 | Reuters
EM on With cash tight, Sears REIT deal takes on new importance Q - "A billion dollars probably isn't going to be enough for the year. My assumption is they are going to keep burning the furniture to keep the store open."
Copyright © 2015. Gimme Credit LLC. All Rights Reserved.
For Public Relations and Press Contact
Susan Assadi sassadi@gimmecredit.com or 800.922.8792